GlassScriptPhysician profile
Rachel E Goodman
NPI 1245792563
$3,538.87
in general payments reported to CMS, 2019-2025
20 companies · $1,798 in 2025
The $1,798 reported for 2025 was more than what 97% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $296 · 2024: $1,446 · 2025: $1,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,830 · Travel and Lodging: $1,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,830.27 |
| Travel and Lodging | $1,708.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $2,729.28 | 2024-2025 | Barostim Neo System |
| Abiomed | $119.93 | 2025 | |
| Alnylam Pharmaceuticals INC. | $104.76 | 2023-2025 | Onpattro, Amvuttra |
| Amgen INC. | $104.21 | 2023 | Repatha |
| Pfizer INC. | $80.44 | 2023-2024 | |
| Daiichi Sankyo INC. | $73.65 | 2023-2024 | Injectafer |
| Angiodynamics, INC. | $41.00 | 2024 | Alphavac |
| Astrazeneca Pharmaceuticals LP | $34.69 | 2024-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $31.83 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.11 | 2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.35 | 2025 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $22.71 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $22.38 | 2025 | Opsumit |
| Abbott Laboratories | $21.68 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Novo Nordisk INC | $21.54 | 2023 | Ozempic |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $19.11 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $16.94 | 2025 | Verquvo |
| Medtronic, INC. | $15.48 | 2024 | Invos |
| Cardiva Medical, INC. | $14.70 | 2023 | Cardiva Vascade 6/7f Vcs |
| Novartis Pharmaceuticals Corporation | $13.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.